How can a biotech startup successfully accumulate over b billion in funding across four years while maintaining a low public profile? For Treeline Biosciences, this silence was a deliberate strategy. Operating away from public scrutiny, Treeline has methodically developed a robust pipeline of innovative programs, with its leading initiatives focused on cancer drugs targeting established mechanisms in novel or potentially superior ways. With an additional $200 million recently secured, Treeline is beginning to reveal insights into its operations and the advancements it has achieved in early clinical development.
The latest financing represents an extension of Treeline’s Series A funding round, as announced by the Watertown, Massachusetts-based company on Wednesday. This funding round includes a diverse group of prominent investors who are enthusiastic about Treeline’s vision for transforming the landscape of drug discovery and financing.
In the typical model for emerging biotech companies, funding is often tied to reaching specific milestones, as noted by Treeline co-founder and CEO Josh Bilenker in a blog post on Wednesday. Adopting this conventional approach could compel Treeline to prioritize immediate goals and focus on a single lead program. Instead, Treeline encouraged its investors to finance a strategy of “repeated invention,” which supports multiple, yet complementary, programs. This innovative funding approach has afforded Treeline the flexibility to thoroughly evaluate each program prior to advancing into clinical trials, as well as the ability to discontinue underperforming initiatives.
“We have discontinued programs when we could not identify effective chemistry hits, when we encountered negative or ambiguous data in efficacy models, or when suitable efficacy models were lacking. We also moved on due to concerns about safety, inadequate absorption, distribution, metabolism, and excretion, as well as when competitors released superior data first,” Bilenker elaborated. “Having the freedom to pivot away from less promising programs is arguably the most valuable advantage our funding strategy has provided us.”
On Wednesday, Treeline unveiled details about three promising cancer programs, including two that were developed internally and one that has been in-licensed. The internally developed TLN-121 is designed to degrade BCL6, a protein that specific lymphoma cells exploit to silence growth-inhibiting genes. A Phase 1 clinical trial is currently enrolling patients diagnosed with B-cell and T-cell lymphomas.
The second internal program, TLN-372, acts as an inhibitor of the KRAS mutation, known for its difficulty in treatment and its role in driving cancer proliferation. Existing FDA-approved small molecule inhibitors include Amgen’s Lumakras and Bristol Myers Squibb’s Krazati, both targeting the KRAS G12C mutation. In contrast, TLN-372 is a pan-KRAS small molecule inhibitor that effectively targets various KRAS variants. Treeline is currently conducting a Phase 1 study with patients suffering from KRAS-altered solid tumors. This competitive market includes other companies such as Revolution Medicines, Astellas Pharma, Amgen, and BridgeBio Oncology Therapeutics, all of whom are also developing pan-KRAS inhibitors.
The third program disclosed by Treeline is TLN-254, a drug licensed from Jiansu Hengrui Pharmaceuticals, which had previously advanced this medication to Phase 2 testing for refractory lymphoma. This small molecule acts as an inhibitor of EZH2, a protein that is either overexpressed or mutated in various cancers. Treeline is currently testing TLN-254 in a Phase 1 study that is enrolling patients with peripheral T-cell lymphomas and cutaneous T-cell lymphomas. Additionally, a fourth program targeting an undisclosed mechanism is on track for an investigational new drug application filing anticipated in early 2026.
Treeline’s innovative approach to drug discovery integrates both laboratory and computational techniques under a single umbrella. While many startups claim to have a similar model, Bilenker emphasizes that Treeline does not confine itself to any specific therapeutic area or platform technology. Instead, the company focuses on meticulously chosen targets employing the most advanced technology available, ensuring they are well-positioned for success.
Bilenker’s impressive background includes founding Loxo Oncology, which Eli Lilly acquired in 2019 for an astounding $8 billion. Treeline’s co-founder and Chief Science Officer, Jeff Engelman, previously served as the global head of oncology at the Novartis Institutes for BioMedical Research. While the oncology expertise of both leaders is apparent in Treeline’s pipeline, the startup asserts on its website that insights gained through cancer research also inform their endeavors in other therapeutic domains. The company actively explores areas such as autoimmune diseases and neurological disorders whenever they identify a distinctive opportunity.
Founded in early 2021 and based in Watertown, Treeline has gradually unveiled its operations. In 2022, the startup announced the addition of KKR to its investor group, highlighting a significant capital commitment that further solidified its financial foundation. At that time, securities filings indicated that the company had successfully raised over $261 million.
To date, Treeline has reported a total fundraising amount of approximately $1.1 billion. The startup’s impressive list of investors includes AI Life Sciences, an affiliate of Access Industries; Arch Venture Partners; OrbiMed; GV; KKR; accounts managed by T. Rowe Price Associates; Ajax Health/Zeus; Casdin Capital; Fidelity Management & Research Company; Aisling Capital; Rock Springs Capital; and Exor.
For more updates on the latest trends in litigation, regulation, deals, and financial services, consider subscribing to Finance Docket, a collaborative effort between Breaking Media publications Above the Law and Dealbreaker.
